153 related articles for article (PubMed ID: 33216947)
1. The effect of topical sirolimus on superficial Kaposiform haemangioendothelioma.
Liu YX; Zhang J; Nie XL; Chen YL; Wang ZY; Xu ZG
Australas J Dermatol; 2021 May; 62(2):e329-e331. PubMed ID: 33216947
[No Abstract] [Full Text] [Related]
2. A case of kaposiform haemangioendothelioma successfully and safely treated with sirolimus.
Wlodek C; Burt H; Shaw L
Clin Exp Dermatol; 2017 Oct; 42(7):825-827. PubMed ID: 28703334
[No Abstract] [Full Text] [Related]
3. Kaposiform haemangioendothelioma in an adult: lack of response to topical sirolimus and response to radiotherapy.
Der Sarkissian SA; Wong XL; Kossard S; Hong A; Sebaratnam DF
Clin Exp Dermatol; 2022 Jan; 47(1):192-193. PubMed ID: 34480811
[TBL] [Abstract][Full Text] [Related]
4. Successful Management of Pancreatic Kaposiform Hemangioendothelioma With Sirolimus: Case Report and Literature Review.
Wang C; Li Y; Xiang B; Li F; Chen S; Li L; Ji Y
Pancreas; 2017; 46(5):e39-e41. PubMed ID: 28426496
[No Abstract] [Full Text] [Related]
5. Sirolimus therapy for children with problematic kaposiform haemangioendothelioma and tufted angioma.
Tasani M; Ancliff P; Glover M
Br J Dermatol; 2017 Dec; 177(6):e344-e346. PubMed ID: 28485019
[No Abstract] [Full Text] [Related]
6. Sirolimus for treatment of Kaposiform haemangioendothelioma with Kasabach-Merritt phenomenon: a retrospective cohort study.
Zhang G; Chen H; Gao Y; Liu Y; Wang J; Liu XY
Br J Dermatol; 2018 May; 178(5):1213-1214. PubMed ID: 29388191
[No Abstract] [Full Text] [Related]
7. Sirolimus for Kaposiform Hemangioendothelioma With Kasabach-Merritt Phenomenon in Two Infants.
Wang Y; Kong L; Sun B; Cui J; Shen W
J Craniofac Surg; 2020 Jun; 31(4):1074-1077. PubMed ID: 32176003
[TBL] [Abstract][Full Text] [Related]
8. Decreased vascularization of retroperitoneal kaposiform hemangioendothelioma induced by treatment with sirolimus explains relief of symptoms.
Iacobas I; Simon ML; Amir T; Gribbin CE; McPartland TG; Kaufman MR; Calderwood S; Nosher JL
Clin Imaging; 2015; 39(3):529-32. PubMed ID: 25662209
[TBL] [Abstract][Full Text] [Related]
9. Successful treatment of kaposiform lymphangiomatosis with sirolimus.
Wang Z; Li K; Yao W; Dong K; Xiao X; Zheng S
Pediatr Blood Cancer; 2015 Jul; 62(7):1291-3. PubMed ID: 25598153
[TBL] [Abstract][Full Text] [Related]
10. Low dose sirolimus treatment for refractory tufted angioma and congenital kaposiform hemangioendothelioma, both with Kasabach-Merritt phenomenon.
Mariani LG; Schmitt IR; Garcia CD; Kiszewski AE
Pediatr Blood Cancer; 2019 Aug; 66(8):e27810. PubMed ID: 31087627
[No Abstract] [Full Text] [Related]
11. Rapidly enlarging "bruise" on the back of an infant. Kaposiform hemangioendothelioma complicated by Kasabach-Merritt syndrome.
Chan S; Cassarino DS
JAMA Dermatol; 2013 Nov; 149(11):1337-8. PubMed ID: 24005816
[No Abstract] [Full Text] [Related]
12. Development of Kasabach-Merritt phenomenon following vaccination: More than a coincidence?
Ji Y; Chen S; Yang K; Xia C; Peng S
J Dermatol; 2018 Oct; 45(10):1203-1206. PubMed ID: 30118141
[TBL] [Abstract][Full Text] [Related]
13. Kaposiform hemangioendothelioma with Kasabach-Merritt phenomenon in an infant: Successful treatment with prednisolone, vincristine, and addition of sirolimus.
Cashell J; Smink GM; Helm K; Xavier F
Pediatr Blood Cancer; 2018 Dec; 65(12):e27305. PubMed ID: 30070028
[TBL] [Abstract][Full Text] [Related]
14. Kaposiform hemangioendothelioma with Kasabach-Merritt phenomenon: from vincristine to sirolimus.
Jahnel J; Lackner H; Reiterer F; Urlesberger B; Urban C
Klin Padiatr; 2012 Oct; 224(6):395-7. PubMed ID: 23070861
[No Abstract] [Full Text] [Related]
15. Sirolimus therapy for kaposiform hemangioendothelioma with long-term follow-up.
Wang Z; Yao W; Sun H; Dong K; Ma Y; Chen L; Zheng S; Li K
J Dermatol; 2019 Nov; 46(11):956-961. PubMed ID: 31489702
[TBL] [Abstract][Full Text] [Related]
16. Sirolimus, a promising treatment for refractory Kaposiform hemangioendothelioma.
Kai L; Wang Z; Yao W; Dong K; Xiao X
J Cancer Res Clin Oncol; 2014 Mar; 140(3):471-6. PubMed ID: 24464150
[TBL] [Abstract][Full Text] [Related]
17. Sirolimus as initial therapy for kaposiform hemangioendothelioma and tufted angioma.
Wang H; Guo X; Duan Y; Zheng B; Gao Y
Pediatr Dermatol; 2018 Sep; 35(5):635-638. PubMed ID: 29999213
[TBL] [Abstract][Full Text] [Related]
18. Kaposiform hemangioendothelioma with Kasabach-Merritt syndrome: successful treatment with sirolimus.
Reichel A; Hamm H; Wiegering V; Wiewrodt B; Neubauer H; Ernestus K; Winkler B
J Dtsch Dermatol Ges; 2017 Mar; 15(3):329-331. PubMed ID: 28220608
[No Abstract] [Full Text] [Related]
19.
Russell TB; Rinker EK; Dillingham CS; Givner LB; McLean TW
Pediatrics; 2018 Apr; 141(Suppl 5):S421-S424. PubMed ID: 29610164
[TBL] [Abstract][Full Text] [Related]
20. Retroperitoneal kaposiform hemangioendothelioma complicated by Kasabach-Merritt phenomenon and obstructive jaundice: A retrospective series of 3 patients treated with sirolimus.
Yao W; Li K; Wang Z; Dong K; Zheng S
Pediatr Dermatol; 2020 Jul; 37(4):677-680. PubMed ID: 32212177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]